Co-evolution of activity and thermostability of an aldo-keto reductase KmAKR for asymmetric synthesis of statin precursor dichiral diols
Shuai Qiu,Feng Cheng,Ling-Jun Jin,Yi Chen,Shu-Fang Li,Ya-Jun Wang,Yu-Guo Zheng
DOI: https://doi.org/10.1016/j.bioorg.2020.104228
IF: 5.307
2020-10-01
Bioorganic Chemistry
Abstract:<p>Aldo-keto reductase <em>Km</em>AKR-catalyzed asymmetric reduction offers a green approach to produce dichiral diol <em>tert</em>-butyl 6-substituted-(3<em>R</em>,5<em>R</em>/<em>S</em>)-dihydroxyhexanoates, which are important building blocks of statins. In our previous work, we cloned a novel gene of NADPH-specific aldo-keto reductase <em>Km</em>AKR (<strong>WT</strong>) from a thermotolerant yeast <em>Kluyveromyces marxianus</em> ZJB14056 and a mutant <em>Km</em>AKR-W297H/Y296W/K29H (<strong>Variant III</strong>) has been constructed and displayed strict diastereoselectivity towards <em>tert</em>-butyl 6-cyano-(5<em>R</em>)-hydroxy-3-oxohexanoate ((5<em>R</em>)-<strong>1</strong>) but moderate activity and stability. Herein, to further co-evolve its activity and thermostability, we performed semi-rational engineering of <strong>Variant III</strong> by using a combinational screening strategy, consisting of tertiary structure analysis, loop engineering, and alanine scanning. As results, the "best" variant <em>K</em>mAKR-W297H/Y296W/K29H/Y28A/T63M (<strong>Variant VI</strong>) was acquired, whose <em>K</em><sub>m</sub>, <em>k</em><sub>cat</sub>/<em>K</em><sub>m</sub> towards (5<em>R</em>)-<strong>1</strong> was 0.66 mM and 210.77 s<sup>−1</sup> mM<sup>−1</sup>, respectively, with improved thermostability (half-life of 14.13 h at 40 °C). Combined with 1.5 g dry cell weight (DCW) L<sup>-1</sup> <em>Exiguobacterium sibiricum</em> glucose dehydrogenase (<em>Es</em>GDH) for NADPH regeneration, 4.5 g DCW L<sup>-1</sup> <strong>Variant VI</strong> completely reduced (5<em>R</em>)-<strong>1</strong> of up to 450 g L<sup>−1</sup> within 7.0 h at 40 °C, yielding the corresponding optically pure <em>tert</em>-butyl 6-cyano-(3<em>R</em>,5<em>R</em>)-dihydroxyhexanoate ((3<em>R</em>,5<em>R</em>)-<strong>3</strong>, >99.5% <em>d.e.</em><sub>p</sub>) with a space–time yield (STY) of 1.24 kg L<sup>−1</sup> day<sup>−1</sup>, and this was the highest level documented in literatures so far on substrate loading and STY of producing (3<em>R</em>,5<em>R</em>)-<strong>3</strong>. Besides (5<em>R</em>)-<strong>1</strong>, <strong>Variant VI</strong> displayed strong activity on <em>tert</em>-butyl 6-chloro-(5<em>S</em>)-hydroxy-3-oxohexanoate ((5<em>S</em>)-<strong>2</strong>). 4.5 g DCW L<sup>-1</sup> <strong>Variant VI</strong> completely reduced 400 g L<sup>−1</sup> (5<em>S</em>)-<strong>2</strong>, within 5.0 h at 40 °C, yielding optically pure <em>tert</em>-butyl 6-chloro-(3<em>R</em>,5<em>S</em>)-dihydroxyhexanoate ((3<em>R</em>,5<em>S</em>)-<strong>4</strong>, >99.5% <em>d.e.</em><sub>p</sub>) with a STY of 1.34 kg L<sup>−1</sup> day<sup>−1</sup>. In summary, <strong>Variant VI</strong> displayed industrial application potential in statins biomanufacturing.</p>
biochemistry & molecular biology,chemistry, organic